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Introduction
Steroid sulfatase is an enzyme which cleaves 
sulfate groups from a variety of steroid 
hormones e.g. dehydroepiandrosterone 
sulfate (DHEAS), thereby altering their 
solubility and activity [1]. STS is expressed in 
numerous mammalian tissues, with highest 
expression in the placenta (www.ncbi.nlm.nih.
gov/unigene/); in the developing and adult 
human brain, relatively high STS expression 
and activity is seen in the cortex, thalamus, 
cerebellum, basal ganglia, hippocampus 
and hypothalamus [2,3]. STS deficiency is 
associated with increased developmental 
and mood disorder risk and a number of 
behavioural differences including: inattention, 
increased impulsivity and altered mood 
and social function [4-6]; these behavioural 
differences may be mediated, in part, by 
underlying changes in serotonergic  or 
cholinergic function [7-9]. Depression, prior 
and current history of medical disorders, 
and cognitive impairment, have previously 
been highlighted as important risk factors in 
suicidality [10].   
In both humans and rodents, STS expression 
and activity increases in brain and peripheral 
tissues towards the end of pregnancy and 
into the postpartum period; hence, enzyme 
deficiency or dysfunction could potentially be 
associated with postpartum psychopathology 
[11,12]. Consistent with this, we have recently 
shown that women who are heterozygous for 
genetic mutations encompassing STS are at 
increased risk of postpartum mood disorders 
[4]. We have also demonstrated that female 
mice, in which STS activity is acutely, and 
systemically, inhibited with 667-Coumate 
shortly after giving birth, show altered 
maternal behaviour (specifically anxiety-
related and startle phenotypes) relative to 
vehicle-treated mice; these drug-induced 
behavioural abnormalities can be partially 
reversed by concurrent administration of the 
atypical antipsychotic drug ziprasidone [13].   
To investigate the neurobiology underlying 
the postpartum behavioural phenotypes 
in STS deficient individuals, we compared 
whole brain gene expression in behaviourally-
defined 667-Coumate and vehicle-treated new 
mouse mothers. Given the large between-
group behavioural differences, we suspected 
that screening by microarray would be able 
to readily identify robust gene expression 
differences and candidate biological pathways, 
and we reasoned that analysis of whole brain 
tissue would capture activity changes across 
multiple interacting brain regions (no single 
brain region has yet been especially strongly 
implicated in postpartum mood disorders). We 
successfully identified a number of nominally-
significant gene expression differences, 
implicating a specific biological pathway.    
Methods
Drug administration and behavioural 
analysis
Within 12hr of giving birth, female mice were 
injected with either 10mg/kg 667-Coumate 
or vehicle solution per os (n=12 per group); 
they were then injected with the same 
solution 48hr later, and behaviourally-tested 
12hr after that. Coumate, and its relative 
667-Coumate, provide highly potent and 
specific STS inhibition in rodents (>70% 
enzyme inhibition in liver and brain) 
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when administered in the aforementioned 
manner [14,15]. There is some evidence that 
667-Coumate also binds carbonic anhydrase 
in erythrocytes, an observation which may 
explain its in vivo stability and deliverability 
[16]. Behavioural testing comprised of 
sequential assessment on the elevated plus 
maze, in a locomotor activity chamber, and 
in a startle/prepulse inhibition paradigm. 
A second batch of mice had 667-Coumate 
injections as described above, but also 
ziprasidone injections i.p. 24hr after giving 
birth, and 1hr prior to behavioural testing 
at doses of either 0, 0.3 or 1.0mg/kg (n=11, 
n=11 and n=7 respectively). Between-group 
behavioural measures were compared using 
parametric (two-tailed unpaired t-test or 
One Way ANOVA) or non-parametric (Mann 
Whitney U test or Kruskal Wallis test) statistics 
depending upon normality of the data as 
determined by Shapiro-Wilk test. Results are 
presented as either mean±standard deviation 
of the mean or median with 95% confidence 
intervals determined by bootstrapping for 
normal and non-normal data respectively. 
Experiments were performed according 
to the UK Animal Scientific Procedures Act 
(1986).
Tissue collection, RNA extraction and 
cDNA synthesis
3hr after behavioural testing, subjects were 
culled by cervical dislocation; whole brains 
were immediately removed, bisected sagitally, 
and frozen on dry ice. The 3hr post-behaviour 
timepoint was chosen in order to allow acute 
physiological changes induced by moderately 
aversive behavioural experiences to return to 
baseline. High-quality total RNA was extracted 
from the right hemisphere of the brain using 
RNeasy Plus Universal Midi Kit (Qiagen) 
according to the manufacturer’s instructions. 
For microarray analysis, three biological 
replicates per group were generated, with 
each replicate containing equal amounts of 
RNA pooled from four hemibrains; 260/280 
absorbance ratios of 2.05-2.08 and RIN 
numbers of 9.4-9.8 were recorded for the six 
replicates using Agilent 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA, USA). 20µl 
cDNA solution per hemibrain was synthesised 
from 4-5 µg RNA using RNA-to-cDNA EcoDry 
Premix with random primers (Clontech), and 
was diluted 50-fold with distilled water. 
Microarray hybridisation and 
bioinformatic analysis
Microarray analysis was conducted by Central 
Biotechnology Services at Cardiff University 
according to standard protocols. Briefly, biotin-
labelled targets for the microarray experiment 
were prepared using 100ng of total RNA per 
replicate.  Sense single-stranded cDNA was 
synthesized, fragmented and labelled using the 
Genechip WT PLUS Reagent Kit (Affymetrix) in 
conjunction with the Affymetrix Genechip Poly-A 
RNA Control Kit as described in the User Manual 
(P/N 703174). A hybridization cocktail containing 
the biotinylated target was incubated with 
the GeneChip Mouse 2.0 ST array (Affymetrix) 
at 60rpm for 16hr at 45°C in a Genechip 
Hybridisation Oven 645.  After hybridization, 
non-specifically bound material was removed 
by washing, and specifically-bound target was 
detected using the GeneChip Hybridization, 
Wash and Stain Kit, in conjunction with the 
GeneChip Fluidics Station 450 (Affymetrix). The 
arrays were scanned using a GeneChip 
Scanner 3000 7G (Affymetrix) in conjunction 
with Affymetrix Genechip Command Console 
(AGCC) software. Data were normalised using 
Robust Multiarray Average (RMA); the overall 
pattern of normalised expression data appeared 
equivalent across the six replicates. Differential 
gene expression analysis was performed using 
lmFit and eBayes from the Limma package 
[17]. FDR-corrected and nominal p-values were 
generated for each probe, with values<0.05 
being regarded as nominally statistically-
significant. Pathway analysis was performed 
using Database for Annotation, Visualisation 
and Integrated Discovery version 6.8 (DAVID, 
RRID: SCR_001881) [18]. Raw microarray data are 
available in the ArrayExpress database (http://
www.ebi.ac.uk/arrayexpress, RRID: SCR_002964) 
under accession number E-MTAB-7233.  
Quantitative Polymerase Chain 
Reaction (qPCR)
qPCR was performed using a Rotorgene 
6000 coupled with a CAS1200 automated 
set-up, and utilizing standard consumables 
(Qiagen, Manchester, UK). PCR reactions were 
performed using 5μl cDNA mix and 200nM 
custom-designed primers (Table 1) and 
SensiMix (Bioline, London, UK). qPCR data 
were analysed using ΔCt methods as described 
previously [19] with normalisation to the 
mean of three ‘housekeeping gene standards’ 
(Hprt,  Gapdh and  Rn18s) whose expression 
was significantly (p<0.001) correlated within 
the samples. Groups were compared by either 
Mann-Whitney U test, unpaired t-test or One 
Way ANOVA.
Results
Behavioural and endocrine 
comparison in animals used for 
microarray analysis
A subset of vehicle and 667-Coumate-treated 
mice from [13] which differed maximally on 
pertinent behavioural measures were selected 
Table 1. Primer sequences used for quantitative PCR analysis. Primers were designed to allow optimum amplifi-
cation, to span intron-exon boundaries where possible, and to amplify key coding gene transcripts.
Gene Forward primer 5’-3’ Reverse primer 5’-3’
Gapdh GAACATCATCCCTGCATCCA CCAGTGAGCTTCCCGTTCA
Hprt TTGCTCGAGATGTCATGAAGGA AATGTAATCCAGCAGGTCAGCAA
Rn18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
Cyp2g1 TGTCACACGGGACACTCATT TGGGTAGCGGAAGTATTTGG
Stoml3 TGCAGCAGAGGGAGAAATGA TCGGCAAGGGAAACACAATG
Vmn1r33 GTCATGCTGACCACAAGTGC CAAGTGGCTGTCGCTATGAA
Saa1 GGTCTGGGCTTCTTCCTACC TACCCTCTCCTCCTCAAGCA
Orm3 TCATCATGTTGAGCCTCCTG GTCAGCCACAGCAATGAGAA
Oxt CCATCACCTACAGCGGATCT CACTTGCGCATATCCAGGTC
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for subsequent analysis, with the rationale 
being that these animals would exhibit the 
greatest difference in brain gene expression. 
667-Coumate and vehicle-treated mothers 
differed significantly with respect to numbers of 
rears on the elevated plus maze (57 (95%CI:19-
86.5) vs. 0 (95%CI:0-0), Mann-Whitney U=10.5, 
p<0.0001), latency to enter the open arm of 
the elevated plus maze (2.2(95%CI:2.0-3.0)s vs. 
8.5s(95%CI:3.2-12.2), Mann-Whitney U=28.0, 
p=0.01), and startle response at 120dB covarying 
for bodyweight and baseline activity (51.6±8.7 
vs. 62.5±8.3 abitrary units, t[1,20]=4.61, p=0.04). 
These group differences were not confounded 
by differential locomotor activity as indexed 
by infra-red beam breaks per hour (1118 
(95%CI:925-2284) vs. 1600 (95%CI:786-2143), 
Mann-Whitney U=72.0, p=1.0), nor by number 
of live pups born to each mother (7 (95%CI:6-
8) vs. 7(95%CI:6-8), Mann-Whitney U=71.0, 
p=0.95). The median serum DHEAS:DHEA ratio in 
667-Coumate-treated mothers (n=11) was ~1.6-
fold higher than that in vehicle-treated mothers 
(n=5)(333 vs. 211), indicating efficacy of systemic 
STS inhibition by the drug.  
Significantly-differentially expressed 
genes in the microarray analysis
We identified 1,081 unique differentially-
expressed transcripts with a nominal p-value 
cut-off<0.05; the 24 most highly differentially 
expressed of these (fold change>1.5) are 
listed in Table 2. No significantly differentially 
expressed genes were identified using the 
comparatively stringent cut-off of False 
Discovery Rate (FDR)-corrected p-value of <0.1. 
Pathway analysis
Pathway analysis of the 1,081 differentially-
expressed genes at p<0.05 with the mouse 
genome as background identified only 
one KEGG (Kyoto Encyclopedia of Genes 
and Genomes [20]) pathway, olfactory 
transduction, as being significant (Benjamini-
corrected p=1.8x10-3). The following gene 
ontology (GO) terms for biological pathway 
were significant after correction for multiple 
testing (G-protein coupled receptor signalling 
p=1.2x10-3 and sensory perception of smell 
p=7.5x10-4), as were the following GO terms 
for molecular function (G-protein coupled 
receptor activity p=5.1x10-5 and olfactory 
receptor activity p=1.3x10-4). We tested the 
possibility that identification of the olfactory 
pathway could have been artefactual due to 
the relatively low and variable expression of the 
associated genes, by filtering for low expression 
variability within the following R Package using 
the nsFilter function with default value of var.
cutoff 0.5: https://www.rdocumentation.org/
packages/genefilter/versions/1.54.2/topics/
nsFilter. This analysis resulted in just 213 unique 
genes that were differentially-expressed at 
a nominal p-value<0.05, 35 of which had a 
fold change in expression >1.5 (the 24 genes 
from Table 2 as well as Psg25, 1700047G07Rik, 
Ugt2b5, Vmn1r86, Olfr493, Olfr295, Vmn1r37, 
Olfr800 and Fpr2); for the 213 genes, the KEGG 
pathway ‘olfactory transduction’ remained 
highly significant (p=3.6x10-11), as did the GO 
biological pathway terms ‘G-protein-coupled 
receptor signalling’ and ‘sensory perception of 
smell’ (p=7.9x10-12 and p=1.2x10-12 respectively) 
and the GO molecular function terms ‘G-protein 
coupled receptor activity’ and ‘olfactory 
receptor activity’ (p=9.6x10-17 and 2.4x10-13 
respectively). 
Quantitative PCR (qPCR)
qPCR analysis was performed for five of the 
most highly-differentially expressed genes 
Table 2. Most highly-differentially expressed genes (>1.5 fold change, p<0.05) between vehicle and 667-Cou-
mate-treated whole mouse brain according to microarray analysis
Gene Gene product Fold 
change
Human 
orthologue and 
genomic location
Expression upregulated in 667-Coumate-treated animals
Cyp2g1 Cytochrome P450, family 2, subfamily g, polypeptide 1 2.47 CYP2G1P (19q13.2)
Ighg Immunoglobulin heavy chain (gamma polypeptide) 1.83 None
Gm6890 Unknown 1.71 CTAG2 (Xq28)
Stoml3 Stomatin (Epb7.2)-like 3 1.66 STOML3 (13q13.3)
mir883a microRNA 883a 1.66 None
Vmn1r33 Vomeronasal 1 receptor 33 1.63 None
4930529C04Rik Zinc finger, BED domain containing 4 pseudogene 1.63 None
1700023F02Rik lincRNA 1.56 None
Vmn2r14 Vomeronasal 2, receptor 14 1.50 None
Expression downregulated in 667-Coumate-treated animals
Saa1 Serum amyloid A 1 1.76 SAA1 (11p15.1)
mir133a-2 microRNA 133a-2 1.76 None
Gsdmc3 Gasdermin C3 1.72 GSDMC3 (8q24.21)
Klk1b22 Kallikrein 1-related peptidase b22 1.66 KLK1 (19q13.33)
Orm3 Orosomucoid 3 1.60 ORM2 (9q32)
Dynlt1b Dynein light chain Tctex-type 1B 1.58 DYNLT1 (6q25.3)
Olfr1454 Olfactory receptor 1454 1.56 OR5B3 (11q12)
Svs3b Seminal vesicle secretory protein 3B 1.56 None
AF357399 snoRNA 1.56 None
Olfr851 Olfactory receptor 851 1.55 OR7G2 (19p13.2)
Olfr1039 Olfactory receptor 1039 1.54 None
Olfr1054 Olfactory receptor 1054 1.54 OR8K3 (11q12.1)
Olfr911-ps1 Olfactory receptor 911, pseudogene 1 1.54 None
Aldoart1 Aldolase 1 A, retrogene 1 1.53 ALDOA (16p11.2)
Olfr1255 Olfactory receptor 1255 1.52 OR4C12 
(11p11.12)
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from Table 2, as well as for Oxt (downregulated 
1.33-fold, nominal p<0.005 in the microarray 
analysis). Oxt encodes the oxytocin protein 
important in maternal physiology, the abnormal 
expression of which has been implicated in 
postpartum mood disorders [21,22]. Whilst 
the direction of expression difference was 
generally consistent across the microarray 
and qPCR analyses for these genes, only two 
genes (Cyp2g1 and Stoml3) were significantly 
differentially-expressed according to qPCR 
(U=34.0, one-tailed p=0.014 and t[15.3]=-1.83, 
one-tailed p=0.04 respectively)(Figure 1); for 
the remaining four genes, p>0.075. We next 
tested whether Cyp2g1 and Stoml3 expression 
was sensitive to the co-administration of 
vehicle or ziprasidone (0.3mg/kg or 1.0mg/kg) 
in 667-Coumate treated animals; the expression 
of neither of these genes was affected: Cyp2g1 
(F[2,28]=0.58, p=0.57) and Stoml3 (F[2,28]=2.83, 
p=0.08)(Figure 2).     
Discussion
Although our vehicle and 667-Coumate 
treated groups differed substantially both in 
terms of their behaviour and with respect to a 
peripheral endocrine marker of STS inhibition 
(DHEAS:DHEA ratio), and the microarray 
experiment was performed with standard 
quality control procedures, we identified 
surprisingly few gene expression differences 
between the groups; those changes which we 
did identify by microarray were relatively small 
in magnitude and several were not significantly 
different by quantitative PCR. These data 
indicate that, at least at the timepoint 
we assayed, large brain gene expression 
differences do not substantially contribute 
towards abnormal maternal behaviour in the 
STS inhibition mouse model, and suggest that 
the behavioural differences are associated 
with another underlying biological mechanism 
e.g. the aggregate effect of small expression 
changes across many genes. This idea is 
consistent with our previous observations 
of: a) few large, statistically-significant, gene 
expression differences between whole brain 
samples from male mice lacking the Sts gene 
and wildtype animals [23] despite considerable 
between-group behavioural differences [6-
8, 24-26] and b) evidence that small brain 
expression changes (<1.5-fold) detectable 
between 667-Coumate and vehicle-treated 
mice by qPCR, but not detectable by the 
present microarray study, might be associated 
with postpartum behavioural phenotypes [13]. 
We did not identify any overlap between genes 
significantly differentially expressed in the 
current study, and those whose expression was 
altered in whole brain from Sts-deficient male 
mice [23], and nor was there any overlap with 
genes whose skin expression was altered in 
male patients with steroid sulfatase deficiency 
[27]; hence, the genetic mechanisms associated 
with acute STS inhibition in females and 
constitutive STS deficiency in males may be 
largely dissociable.
We did observe robust upregulation of the 
Cyp2g1 and Stoml3 genes (~3-fold and 1.5-
fold respectively) in 667-Coumate treated 
whole brain. The expression of both genes 
is restricted to the olfactory system in mice 
[28,29]. CYP2G1 is a major P450 enzyme in 
the olfactory mucosa of rodents, and, whilst 
its absence in homozygous knockout mice 
does not appear to impair olfaction, it does 
result in altered steroid hormone metabolism 
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Figure 1. Comparison of gene expression in vehicle and 667-Coumate treated whole mouse brain by quantitative PCR. Boxes show interquartile range with median and 
mean (bold line) values, and whiskers represent 5% and 95% confidence intervals. *p<0.05.  
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and metabolic activation of coumarin [28]. 
Increased expression of Cyp2g1 following 
administration of 667-Coumate, a tricyclic 
coumarin sulfamate [30], is perhaps, therefore, 
unsurprising, and further evidence that the 
drug is influencing neurophysiology. In man, 
functional Cyp2g1  orthologues appear to 
be rare [31]. Whilst the biological roles of 
STOML3 remain to be fully clarified, there 
is some evidence that the protein mediates 
mechanosensory processes [32]. The elevated 
expression of Cyp2g1 and Stoml3 genes in 
667-Coumate-treated mouse brain could 
not be reduced through antipsychotic 
(ziprasidone) adminstration, indicating that 
these genes and their asociated proteins are 
unlikely to play a large role in mediating the 
rescue effect of ziprasidone on aspects of 
maternal behaviour.  
Pathway analysis incorporating all 
nominally-significant microarray hits (including 
those with low differential expression) 
suggested that 667-Coumate may perturb 
olfactory transduction processes and that 
this perturbation may mediate drug-induced 
effects on postpartum maternal behaviour 
in the mouse; potentially, the increased 
prevalence of postpartum mood disorder in STS 
deficient women may be partially attributable 
to abnormalities within the olfactory system 
and/or its links to the limbic system. This 
possibility is feasible in light of the clinical 
observation that therapeutic 667-Coumate 
administration can elicit taste disturbances 
in female patients [33], and is consistent with 
an extensive literature on the importance of 
olfactory (and associated limbic) function in 
mammalian mothers [34], with evidence that 
several steroid sulfates act as ligands within 
the mouse accessory olfactory system [35], 
with the expression of multiple olfactory 
receptors within human brain tissue [36], and 
with recent findings that olfactory processes 
are perturbed in both a genetic mouse model 
of abnormal maternal behaviour [37] and 
multiple mood disorders [38]. With regard 
to specific candidate genes of interest, both 
[37] and the present study highlighted Olfr59 
expression as being significantly upregulated 
(~1.4-fold, p<0.05) in hypothalamus and whole 
brain respectively in mothers with maternal 
behavioural abnormalities; this gene has no 
clear human orthologue. Potentially, olfactory 
abnormalities could predispose to postpartum 
mood problems via impairing mother-
offspring bonding and social judgment, 
through increasing sensory anhedonia, or 
through increasing levels of stress [38,39]. 
Additionally, it is important to recognise that 
olfactory abnormalities are likely to be only one 
of many biological mechanisms contributing 
to altered maternal behaviour.        
Our study is limited in two main ways. First, 
we examined gene expression across the 
whole brain. Whilst this strategy is useful for 
capturing widespread expression changes 
and is sensible given our lack of knowledge 
about the underlying neuroanatomy of 
postpartum mood disorders, it is unlikely to 
detect gene expression changes between 
groups that are regionally-specific. Second, 
microarray technology, whilst cheap and 
easily implementable, is relatively insensitive 
to small gene expression changes, and has 
low resolution with regard to determining 
differentially expressed splice variants [40]. 
Hence, future between-group comparisons 
might use a more specific, and more 
sensitive, technique such as RNA sequencing 
to assay gene expression in selected brain 
regions of importance to maternal behaviour 
and mood regulation, and whose chemistry 
is known to be altered by STS deficiency e.g. 
hippocampus.      
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Figure 2. Comparison of gene expression in whole mouse brain by quantitative PCR in animals administered 667-Coumate and either 0, 0.3 or 1.0mg/kg ziprasidone. Boxes 
show interquartile range with median and mean (bold line) values, and whiskers represent 5% and 95% confidence intervals.
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